Clinical trial · Observational
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
NCT01163526CI-TRIAL-00025677terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): accrual
Summary
Brief summary (as posted)
A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain (Nervous System) Cancers | — | UNRESOLVED | — |
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Colon/Rectal Cancer | — | UNRESOLVED | — |
| Hepatobiliary Cancers | Malignant Hepatobiliary Neoplasm | ALIAS | 0.90 |
| Hepatocellular Carcinoma (Hepatoma) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Liver | — | UNRESOLVED | — |
| Neuroendocrine Tumors | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT perfusion | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- neuroendocrine metastases
- description
- 15 patients with neuroendocrine metastases
- interventionNames
- Procedure: CT perfusion
- label
- colon cancer metastases
- description
- 15 patients with colon cancer metastases
- interventionNames
- Procedure: CT perfusion
- label
- HCC treated with cyberknife radiation and chemotherapy
- description
- 15 patients with HCC treated with cyberknife radiation and chemotherapy
- interventionNames
- Procedure: CT perfusion
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:3.1.1 Patients with suspected or biopsy-proven liver masses including unresectable hepatocellular carcinoma (HCC), unresectable colon cancer metastases to the liver, and metastatic neuroendocrine tumors to the liver will be eligible for enrollment. 3.1.2 Patients who have undergone prior chemotherapy more than one year prior to the study are eligible for enrollment. 3.1.4 Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant. 3.1.5 No life expectancy restrictions. 3.1.6 ECOG and Karnofsky Performance Status will not be employed. 3.1.7 Patients with renal failure are ineligible for this study (Glomerular filtration rate (GFR) must be \> 60) 3.1.8 Ability to understand and willingness to sign a written informed consent document. Exclusion Criteria:3.2.1 Patients who have undergone prior chemoembolization of hepatocellular carcinoma (HCC) are ineligible for enrollment. Patients who have undergone chemotherapy within one year prior to the study are also ineligible for enrollment. 3.2.2 No restrictions regarding use of other investigational agents. 3.2.3 Patients with severe contrast allergy are ineligible. 3.2.4 Patients who are pregnant or are trying to become pregnant are excluded from this study. 3.2.5 Patients who are cancer survivors or Human Immunodeficiency Virus (HIV)-positive will not be excluded.
References
Publications (0)
Data not yet available
No reference posted for this study.